FDA Approves First Targeted Therapy For Rare Blood Disorder.

Reuters (2/6, Maddipatla) reports the FDA approved Sanofi’s caplacizumab (Cablivi) in combination with standard treatment for acquired thrombotic thrombocytopenic purpura (aTTP), “a life-threatening, autoimmune disorder characterized by clot formation in...